Treatment Options for Metastatic Gastrointestinal Stromal Tumors to the Liver: A Review

Abstract

Up to half of patients with a gastrointestinal stromal tumor (GIST) will present with metastatic disease, most commonly involving the liver. Prior to the introduction of tyrosine kinase inhibitors, treatment options were limited for patients with metastatic GIST to the liver resulting in dismal survival rates. However, with the advent of effective systemic chemotherapy and continued advancements in both surgical and local adjunctive therapy options, significant improvements in survival have been achieved. In this review, the authors characterize the evolution of the treatment approach for metastatic GIST to the liver, including the roles of both surgical resection and adjunctive therapies in today's practice.

Keywords

stromal tumors - GIST - metastatic

• References

• 1 Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3 (11) 655-664
• 2 Nilsson B, Bümming P, Meis-Kindblom JM. , et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103 (04) 821-829
• 3 Turley RS, Peng PD, Reddy SK. , et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer 2012; 118 (14) 3571-3578
• 4 Quek R, George S. Gastrointestinal stromal tumor: a clinical overview. Hematol Oncol Clin North Am 2009; 23 (01) 69-78 , viii
• 5 Agaimy A, Wünsch PH. Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg 2009; 394 (02) 375-381
• 6 Vassos N, Agaimy A, Hohenberger W, Croner RS. Extraabdominal lymph node metastasis in gastrointestinal stromal tumors (GIST). J Gastrointest Surg 2011; 15 (07) 1232-1236
• 7 Keung EZ, Fairweather M, Raut CP. The role of surgery in metastatic gastrointestinal stromal tumors. Curr Treat Options Oncol 2016; 17 (02) 8
• 8 Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152 (05) 1259-1269
• 9 Hirota S, Isozaki K, Moriyama Y. , et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279 (5350): 577-580
• 10 Demetri GD, von Mehren M, Antonescu CR. , et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8 (Suppl. 02) S1-S41 , quiz S42–S44
• 11 Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol 2012; 1 (01) 14
• 12 Tielen R, Verhoef C, van Coevorden F. , et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?. World J Surg Oncol 2012; 10: 111
• 13 DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234 (04) 540-547 , discussion 547–548
• 14 Foster JH. Survival after liver resection for secondary tumors. Am J Surg 1978; 135 (03) 389-394
• 15 Jaques DP, Coit DG, Casper ES, Brennan MF. Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221 (04) 392-397
• 16 Nunobe S, Sano T, Shimada K, Sakamoto Y, Kosuge T. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol 2005; 35 (06) 338-341
• 17 Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141 (06) 537-543 , discussion 543–544
• 18 Husted TL, Neff G, Thomas MJ, Gross TG, Woodle ES, Buell JF. Liver transplantation for primary or metastatic sarcoma to the liver. Am J Transplant 2006; 6 (02) 392-397
• 19 Serralta AS, Sanjuan FR, Moya AH. , et al. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol 2004; 16 (11) 1237-1239
• 20 Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol 2006; 17 (Suppl. 10) x280-x286
• 21 Demetri GD, von Mehren M, Blanke CD. , et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (07) 472-480
• 22 Blanke CD, Rankin C, Demetri GD. , et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26 (04) 626-632
• 23 Casali PG, Abecassis N, Bauer S. , et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv68-iv78
• 24 Haller F, Detken S, Schulten H-J. , et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007; 14 (02) 526-532
• 25 Chen LL, Trent JC, Wu EF. , et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64 (17) 5913-5919
• 26 Heinrich MC, Corless CL, Demetri GD. , et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21 (23) 4342-4349
• 27 Antonescu CR, Besmer P, Guo T. , et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11 (11) 4182-4190
• 28 Zhu J, Yang Y, Zhou L, Jiang M, Hou M. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer 2010; 10: 199
• 29 von Mehren M, Randall RL, Benjamin RS. , et al. Soft tissue sarcoma, version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16 (05) 536-563
• 30 DeMatteo RP. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?. Ann Surg Oncol 2007; 14 (01) 1-2
• 31 Verweij J, Casali PG, Zalcberg J. , et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127-1134
• 32 Sym SJ, Ryu MH, Lee JL. , et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol 2008; 98 (01) 27-33
• 33 DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245 (03) 347-352
• 34 Bauer S, Rutkowski P, Hohenberger P. , et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 2014; 40 (04) 412-419
• 35 Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009; 23 (01) 115-127, ix ix.
• 36 Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13 (10) 1271-1280
• 37 Shindoh J, Truty MJ, Aloia TA. , et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216 (02) 201-209
• 38 Mussi C, Ronellenfitsch U, Jakob J. , et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. Ann Oncol 2010; 21 (02) 403-408
• 39 Machairas N, Prodromidou A, Molmenti E, Kostakis ID, Sotiropoulos GC. Management of liver metastases from gastrointestinal stromal tumors: where do we stand?. J Gastrointest Oncol 2017; 8 (06) 1100-1108
• 40 Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. ; ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 04) 64-67
• 41 ClinicalTrials.gov. SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST - Full Text View (n.d.). https://clinicaltrials.gov/ct2/show/NCT02924714 . Accessed 12 October, 2018.
• 42 Hompland I, Bruland OS. Can imatinib be safely withdrawn in patients with surgically resected metastatic GIST?. Anticancer Res 2015; 35 (11) 5759-5765
• 43 Seesing MF, Tielen R, van Hillegersberg R. , et al; Dutch Liver Surgery Working Group. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol 2016; 42 (09) 1407-1413
• 44 Cheung TT, Chok KS, Chan AC. , et al. Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour. ANZ J Surg 2014; 84 (11) 827-831
• 45 Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 2010; 40 (10) 936-942
• 46 Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol 2015; 14 (04) 531-539
• 47 Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg 1998; 2 (02) 151-155
• 48 Shima Y, Horimi T, Ishikawa T. , et al. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg 2003; 10 (01) 77-80
• 49 Gomez D, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: a single centre experience. HPB (Oxford) 2007; 9 (01) 64-70
• 50 de la Fuente SG, Deneve JL, Parsons CM, Zager JS, Conley AP, Gonzalez RJ. A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. HPB (Oxford) 2013; 15 (09) 655-660
• 51 Brudvik KW, Patel SH, Roland CL. , et al. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg 2015; 19 (08) 1476-1483
• 52 Cananzi FC, Belgaumkar A, Lorenzi B, Mudan S. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. ANZ J Surg 2014; 84 (12) 937-942
• 53 Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 2016; 263 (01) 146-152
• 54 Ye YJ, Gao ZD, Poston GJ, Wang S. Diagnosis and multi-disciplinary management of hepatic metastases from gastrointestinal stromal tumour (GIST). Eur J Surg Oncol 2009; 35 (08) 787-792
• 55 Yamanaka T, Takaki H, Nakatsuka A. , et al. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. J Vasc Interv Radiol 2013; 24 (03) 341-346
• 56 Yoon IS, Shin JH, Han K. , et al. Ultrasound-guided intraoperative radiofrequency ablation and surgical resection for liver metastasis from malignant gastrointestinal stromal tumors. Korean J Radiol 2018; 19 (01) 54-62
• 57 Jung JH, Won HJ, Shin YM, Kim PN. Safety and efficacy of radiofrequency ablation for hepatic metastases from gastrointestinal stromal tumor. J Vasc Interv Radiol 2015; 26 (12) 1797-1802
• 58 Jones RL, McCall J, Adam A. , et al. Radiofrequency ablation is a feasible therapeutic option in the multimodality management of sarcoma. Eur J Surg Oncol 2010; 36 (05) 477-482
• 59 Hakimé A, Le Cesne A, Deschamps F. , et al. A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovasc Intervent Radiol 2014; 37 (01) 132-139
• 60 van Tilborg AA, Scheffer HJ, de Jong MC. , et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol 2016; 39 (10) 1438-1446
• 61 Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. Ultraschall Med 2011; 32 (05) 492-496
• 62 Scheffer HJ, Vroomen LG, Nielsen K. , et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer 2015; 15: 772
• 63 Brown KT, Do RK, Gonen M. , et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 2016; 34 (17) 2046-2053
• 64 Cao G, Li J, Shen L, Zhu X. Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases. World J Gastroenterol 2012; 18 (42) 6134-6140
• 65 Rathmann N, Diehl SJ, Dinter D. , et al. Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors. J Vasc Interv Radiol 2015; 26 (02) 231-238
• 66 Joensuu H, Eriksson M, Collan J, Balk MH, Leyvraz S, Montemurro M. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study. Radiother Oncol 2015; 116 (02) 233-238